We have recently compiled a list of 20 Best Biotech Stocks Under $20 to Buy Now. The eighth stock on our list of the best biotech stocks under $20 is CytomX Therapeutics, Inc.

TheFly reported on January 20 that Piper Sandler raised its price target on CTMX to $10 from $6.50, maintaining an overweight rating. The company noted that initial Phase 1 data for varsetatug maseatecan in heavily pretreated metastatic colorectal cancer showed an overall response rate of 28%, a disease control rate of 94% and a median PFS of 5.8 months. This quarter, updated data with possible dose-dependent benefits from about 100 patients in three treatment cohorts are expected.

Similarly, on the same day, Barclays analyst Etzer Darout also raised his price target on CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $8 from $6 and maintained an overweight rating. The impending colorectal cancer reading was cited by the company as having an attractive risk-reward profile.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a clinical-stage biopharmaceutical company developing Probody therapeutics, conditioning-activated antibody prodrugs designed to improve cancer targeting and reduce off-tumor toxicity. Its pipeline includes innovative immuno-oncology and targeted therapies aimed at improving the safety and efficacy of solid tumors and other serious diseases.

While we recognize CTMX’s potential as an investment, we believe that certain AI stocks offer greater upside potential and less downside risk. If you’re looking for an extremely undervalued AI stock that will also benefit significantly from Trump-era tariffs and the onshoring trend, check out our free report on the best short term AI stock.

READ THE FOLLOWING: 12 Best Multibagger Stocks to Buy Ahead of 2026 i 7 Best Rising Tech Stocks to Buy Now.

Disclosure: no.